Changes of p53 in the Brains of Patients with Alzheimer's Disease

doi:10.1006/bbrc.1997.6301

Biochemical and Biophysical Research Communications

Volume 232, Issue 2, 17 March 1997, Pages 418-421

https://doi.org/10.1006/bbrc.1997.6301 Get rights and content

Abstract

Recent studies suggest that cortical neurons and glial cells undergo apoptosis in Alzheimer's disease (AD). Since the protein p53 is known to induce apoptosis, we assessed p53 in postmortem samples from normal human and AD brains using specific antibody. In AD brains, the amount of p53 in temporal cortex was significantly higher than in controls, and this p53-like immunoreactivity was observed in glial cells. These findings suggest that the p53 may be involved in the apoptosis of glial cells in AD brains, but apoptosis in neurons may occur through a p53-independent pathway.

References (26)

B.A. Yankner
Neuron
(1996)
C. Behl et al.
Brain Res.
(1994)
G. Smale et al.
Exp. Neurol.
(1995)
T.M. Gottlieb et al.
Biochim. Biophys. Acta
(1996)
G. Selivanova et al.
Adv. Canncer Res.
(1995)
M.M. Bradford
Anal. Biochem.
(1976)
M.J. West et al.
Lancet
(1994)
M.A. Smith et al.
Trends Neurosci.
(1995)
C. Behl et al.
Cell
(1994)
U.K. Meβmer et al.
FEBS Lett.
(1994)

K.S. Kulju et al.

Exp. Cell Res.

(1995)

D.T. Loo et al.

Proc. Natl. Acad. Sci. USA

(1993)

Cited by (160)

Molecular Mechanisms of Cellular Senescence in Neurodegenerative Diseases
2023, Journal of Molecular Biology
Neurodegenerative diseases, such as Alzheimer’s and Parkinson’s, are characterized by several pathological features, including selective neuronal loss, aggregation of specific proteins, and chronic inflammation. Aging is the most critical risk factor of these disorders. However, the mechanism by which aging contributes to the pathogenesis of neurodegenerative diseases is not clearly understood. Cellular senescence is a cell state or fate in response to stimuli. It is typically associated with a series of changes in cellular phenotypes such as abnormal cellular metabolism and proteostasis, reactive oxygen species (ROS) production, and increased secretion of certain molecules via senescence-associated secretory phenotype (SASP). In this review, we discuss how cellular senescence contributes to brain aging and neurodegenerative diseases, and the relationship between protein aggregation and cellular senescence. Finally, we discuss the potential of senescence modifiers and senolytics in the treatment of neurodegenerative diseases.
Δ133p53α Protects Human Astrocytes from Amyloid-beta Induced Senescence and Neurotoxicity
2022, Neuroscience
Cellular senescence is an important contributor to aging and age-related diseases such as Alzheimer’s disease (AD). Senescent cells are characterized by a durable cell proliferation arrest and the acquisition of a proinflammatory senescence-associated secretory phenotype (SASP), which participates in the progression of neurodegenerative disorders. Clearance of senescent glial cells in an AD mouse model prevented cognitive decline suggesting pharmacological agents targeting cellular senescence might provide novel therapeutic approaches for AD. Δ133p53α, a natural protein isoform of p53, was previously shown to be a negative regulator of cellular senescence in primary human astrocytes, with clinical implications from its diminished expression in brain tissues from AD patients. Here we show that treatment of proliferating human astrocytes in culture with amyloid-beta oligomers (Aβ), an endogenous pathogenic agent of AD, results in reduced expression of Δ133p53α, as well as induces the cells to become senescent and express proinflammatory SASP cytokines such as IL-6, IL-1β and TNFα. Our data suggest that Aβ-induced astrocyte cellular senescence is associated with accelerated DNA damage, and upregulation of full-length p53 and its senescence-inducing target gene p21^WAF1. We also show that exogenously enhanced expression of Δ133p53α rescues human astrocytes from Aβ-induced cellular senescence and SASP through both protection from DNA damage and dominant-negative inhibition of full-length p53, leading to inhibition of Aβ-induced, astrocyte-mediated neurotoxicity. The results presented here demonstrate that Δ133p53α manipulation could modulate cellular senescence in the context of AD, possibly opening new therapeutic avenues.
The role of microRNA-34 family in Alzheimer's disease: A potential molecular link between neurodegeneration and metabolic disorders
2021, Pharmacological Research
Growing evidence indicates that overexpression of the microRNA-34 (miR-34) family in the brain may play a crucial role in Alzheimer’s disease (AD) pathogenesis by targeting and downregulating genes associated with neuronal survival, synapse formation and plasticity, Aβ clearance, mitochondrial function, antioxidant defense system, and energy metabolism. Additionally, elevated levels of the miR-34 family in the liver and pancreas promote the development of metabolic syndromes (MetS), such as diabetes and obesity. Importantly, MetS represent a well-documented risk factor for sporadic AD. This review focuses on the recent findings regarding the role of the miR-34 family in the pathogenesis of AD and MetS, and proposes miR-34 as a potential molecular link between both disorders. A comprehensive understanding of the functional roles of miR-34 family in the molecular and cellular pathogenesis of AD brains may lead to the discovery of a breakthrough treatment strategy for this disease.
Phenanthroline impairs βAPP processing and expression, increases p53 protein levels and induces cell cycle arrest in human neuroblastoma cells
2021, Brain Research Bulletin
Mis-functional βAPP processing is deemed to be the major phenomenon resulting in increased neuronal cell death, impaired neurogenesis and the loss of synapses, which eventually manifest as the complex symptoms of Alzheimer’s disease. Despite of several milestones having been achieved in the field of drug development, the stigma of the disorder as an incurable disease still remains. Some ADAM proteases mediate the physiological non-amyloidogenic α-secretase processing of βAPP that generates neuroprotective sAPPα production. Earlier studies have also pointed out the role of p53 in Alzheimer’s disease neuropathology, although a direct link with metalloprotease activities remains to be established. In this study, we explored the consequences of α-secretase inhibition on p53 status in cultured human neuroblastoma SH-SY5Y cells by means of specific inhibitors of ADAM10 and ADAM17 and the metal chelator and general metalloprotease inhibitor phenanthroline. We establish that, beyond the ability of all inhibitors to affect sAPPα production to varying degrees, phenanthroline specifically and dose-dependently lessened βAPP expression, a phenomenon that correlated with a strong increase in p53 protein levels and a concomitant decrease of the p53-degrading calpain protease. Furthermore, treatment of cells at concentrations of phenanthroline similar to those inducing increased levels of p53 induced cell cycle arrest leading to apoptosis. Altogether, our results identify new roles of phenanthroline in perturbing βAPP, p53 and calpain biology, and suggest that the use of this compound and its derivatives as antimicrobial and anti-cancer therapies might trigger Alzheimer’s disease pathogenesis.
p53 is a central regulator driving neurodegeneration caused by C9orf72 poly(PR)
2021, Cell
The most common genetic cause of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) is a GGGGCC repeat expansion in the C9orf72 gene. We developed a platform to interrogate the chromatin accessibility landscape and transcriptional program within neurons during degeneration. We provide evidence that neurons expressing the dipeptide repeat protein poly(proline-arginine), translated from the C9orf72 repeat expansion, activate a highly specific transcriptional program, exemplified by a single transcription factor, p53. Ablating p53 in mice completely rescued neurons from degeneration and markedly increased survival in a C9orf72 mouse model. p53 reduction also rescued axonal degeneration caused by poly(glycine-arginine), increased survival of C9orf72 ALS/FTD-patient-induced pluripotent stem cell (iPSC)-derived motor neurons, and mitigated neurodegeneration in a C9orf72 fly model. We show that p53 activates a downstream transcriptional program, including Puma, which drives neurodegeneration. These data demonstrate a neurodegenerative mechanism dynamically regulated through transcription-factor-binding events and provide a framework to apply chromatin accessibility and transcription program profiles to neurodegeneration.
Death-associated protein kinase 1 as a therapeutic target for Alzheimer's disease
2024, Translational Neurodegeneration

View all citing articles on Scopus

^☆: Abbreviations used: AD, Alzheimer's diseaseAβ, β-amyloid;

^☆☆: S. Murphy, Ed.

¹: To whom correspondence should be addressed. FAX: +81(Japan)-75-751-9541.

View full text

Regular ArticleChanges of p53 in the Brains of Patients with Alzheimer's Disease☆,☆☆

Abstract

Neuron

Brain Res.

Exp. Neurol.

Biochim. Biophys. Acta

Adv. Canncer Res.

Anal. Biochem.

Lancet

Trends Neurosci.

Cell

FEBS Lett.

Exp. Cell Res.

Proc. Natl. Acad. Sci. USA

Regular Article
Changes of p53 in the Brains of Patients with Alzheimer's Disease☆,☆☆